Thyroid CancerThyroid Cancer

Thyroid Cancer: Disease and Pipeline

Analysis

Info@ISRreports.com

©2014 Industry Standard Research www.ISRreports.com

PREVIEW

www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 2

act with confidence

Report OverviewThis report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a

view of the thyroid cancer market not available elsewhere. This reports gives an overview of the current and

future thyroid cancer clinical development market, the activities of the key market players, and outlines trial

and commercial regulatory environments.

27 Charts and Graphs

91Pages

6.4%Average annual increase

in thryroid cancer incidence in the U.S.

NEXT: Table of contents and sample pages

Major Sections:1. Disease Overview

2. Epidemiology

3. Diagnosis and Staging

4. Tumour Classification

5. Treatment of Thyroid Cancer

6. Thyroid Cancer Prognosis

7. Environmental Analysis

8. Drug Development in Thyroid Cancer

• Global and country-specific incidence rates for thyroid cancer

• Active development pipeline, including promising new therapies currently in Early and Late Phases of development

• Analysis of clinical trial environments for new thyroid cancer therapies

• Areas of unmet need

What you will learn in this report:

How you can use this report:• Identify and enhance commercial and development opportunities with an in-depth and

current analysis of the global thyroid cancer market

• Understand how products currently in development could impact this market

• Assess the competition with an analysis and summary of companies active in this space

• Brand Managers

• Portfolio Managers

• Research & Development

• Managed Markets

Valuable for:

www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 3

act with confidence

Table of Contents

For full table of contents and additional sample pages, download the full preview from ISR’s website: www.isrreports.com

www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 4

act with confidence

List of Tables

List of Figures

Table 1. Incidence of Thyroid Cancer in the Major Markets

Table 2. Incidence of Thyroid Cancer in Emerging Markets

Table 3. Age at Diagnosis of Thyroid Cancer (US)

Table 4. Incidence Rate of Thyroid Cancer by Ethnicity (US)

Table 5. Thyroid Cancer Mortality in the Major Markets

Table 6. Age at Death from Thyroid Cancer (US)

Table 7. Classification of Primary Tumour, Lymph Nodes and Metastases in Thyroid Cancer

Table 8. Staging for Differentiated Thyroid Cancer in Patients >45 Years and Medullary Thyroid Cancer in Patients of All Ages

Table 9. Staging for Anaplastic Thyroid Cancer

Table 10. Summary of ATA and ETA Tumour Recurrence Risk Stratification

Table 11. 5-Year Relative Survival Based on Stage at Diagnosis

Table 12. Thyroid Cancer - Major Markets Patient Population and Product Environment

Table 13. Thyroid Cancer - Emerging Markets Patient Population and Product Environment

Table 14. Number of Patients in Thyroid Cancer Clinical Trials by Phase

Table 15. Number of Patients in Pharma Sponsored Thyroid Cancer Clinical Trials by Phase

Table 16. Thyroid Cancer Development Pipeline

Figure 1. Thyroid Gland

Figure 2. Global Incidence of Thyroid Cancer, Both Sexes

Figure 3. Countries with the Highest Number of Thyroid Cancer Cases (2012), Both Sexes

Figure 4. Countries with the Highest Number of Annual Deaths from Thyroid Cancer

Figure 5. Geographic Distribution of Open Thyroid Cancer Clinical Trials

Figure 6. Distribution of Industry Sponsored, Open Thyroid Cancer Trials

Figure 7. Distribution of Active Thyroid Cancer Trials, by Phase

Figure 8. Distribution of Active Pharma Industry Sponsored Thyroid Cancer Trials, by Phase

Figure 9. Major intracellular pathways targeted for the treatment of thyroid cancer

www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 5

act with confidence

act with confidence

Chapter 2 - Thyroid Cancer Epidemiology

www.ISRreports.com ©2014 | Thyroid Cancer: Disease and Pipeline Analysis 17

Thyroid Cancer IncidenceThe latest figures from the World Health Organization [1] show that thyroid cancer has a worldwide incidence of just over 298,000 diagnosed cases per year, constituting 2�1% of all cancer incidences� There is a strong gender bias to this figure with 77% of thyroid cancer cases globally being diagnosed in women� As such, thyroid cancer is the 8th most commonly diagnosed cancer in women, accounting for 3�5% of cancer diagnoses, but does not feature in the 15 most common cancers for both sexes combined�

Figure 2. Global Incidence of Thyroid Cancer, Both Sexes

The incidence of thyroid cancer is reported to be rising in many countries and regions� In the US, the incidence of thyroid cancer has been increasing at an average rate of 6�4% each year for the past ten years [Surveillance, Epidemiology, and End Results Registry (SEER)]� Many experts believe this increase is largely a consequence of increased diagnosis of small, papillary tumours, identified using ultrasound techniques and as part of diagnostic work up for other conditions� However, others point to increasing incidence rates of thyroid cancer in countries such as India, where imaging is not prevalent, as evidence to suggest there are other factors responsible for the increasing incidence�

In the major pharmaceutical markets, the US has a significantly higher age standardised rate of thyroid cancer (ASR 13�2) compared to most other countries� This is particularly evident in the age standardised rate among women (ASR 20�0)� While Italy has the next highest total age standardised rate (ASR 10�8), the rate for men is comparable to that of the US (ASR 6�7 and ASR 6�4 respectively), but the rate among women is much lower

Sample Page

www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 6

act with confidence

act with confidence

Chapter 1 – Thyroid Cancer Disease Overview

www.ISRreports.com ©2014 | Thyroid Cancer: Disease and Pipeline Analysis 15

Sources: ISR reports, cancer.org, seer.cancer.gov

radioactive iodine treatment surgerychemotherapy

thyroid hormone therapy

External Beam Radiationtargeted therapy

Treatment

97.8%

Five year survival rate:

Nearly 2/3 cases of thyroid

cancer are found in people

younger than 55 years of age.

Women are three times more likely

to develop thyroid cancer than men.

40+

radiationdiet low in iodine hereditary conditions family historygender and age

Risk Factors

There are often physical

signs of thyroid cancer

present such as lumps, swelling, or nodules.

Thyroid cancer forms

in the thyroid gland,

a butterfly shaped

gland in the front part

of the neck.

is the most rapidly increasing cancer in the U.S.

with 62,980 new cases predicted in 2014.

Thyroid Cancer

75-85%

10-15%

3%

1-6%

5%

1-2%

% of thyroid cancer cases

Papillary

Follicular

Hürthle cell carcinoma

Poorly Di�erentiated Thyroid Carcinoma

Medullary

Anaplastic

Types of thyroid cancer

© Industry Standard Research

Sample Page

www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 7

act with confidence

Sample Page

For full table of contents and additional sample pages, download the full preview from ISR’s website: www.isrreports.com

www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 8

act with confidence

Ordering Information

Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.   For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.

About Industry Standard Research

Save on this, or any ISR report, by

creating a free account

Register now• Receive a $250 instant credit towards any ISR report• Earn 10% credit towards all future purchases• Receive advanced notifications on ISR’s latest reports and free resources

For pricing and ordering information, please visit ISR’s website: www.isrreports.com

www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 9

act with confidence

www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 9

act with confidence

www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 10

act with confidence

www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 10

act with confidence

The ISR DifferenceCustom-quality syndicated market research

www.ISRreports.com

ISR's Reports The Common Syndicated Reportvs.

How confident are you?

vs.Data Collection

ISR's proprietary data collection tools and channels support fast,

high quality data collection

Struggle to recruit the right targets and enough of them

vs.Sample Sizes

Robust sample sizes that instill confidence

Often insufficient industry representation that leaves you

defending results

vs.vs.Research methods

Mostly primary research;

always appropriate for the topic

One size fits all; usually publically

available data

vs.vs.Respondents

Sophisticated screening ensures genuine decision-makers

Undisclosed methodologies and

respondent demographics

vs.vs.Analysts

Decades of experience means more insights that are

immediately usable

Junior analysts capable of reporting numbers